Novel vasopressin V1A and V2 antagonist (Conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia

被引：0
|
作者：
Verbalis, JG
Bisaha, JG
Smith, N
机构：
[1] Yamanouchi Pharma Amer Inc, Paramus, NJ USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
来源：
CIRCULATION | 2004年 / 110卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3346
引用
收藏
页码：723 / 723
页数：1
相关论文
共 50 条
  • [31] Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure
    Smith, WB
    Russell, S
    Ghali, JK
    Painchaud, CA
    Ghazzi, MM
    Konstam, MA
    Udelson, JE
    Selaru, P
    EUROPEAN HEART JOURNAL, 2001, 22 : 541 - 541
  • [32] Structurally novel V2-selective and dual V1A/V2 vasopressin receptor antagonists.
    Dyatkin, AB
    Maryanoff, BE
    Hoekstra, WJ
    Hlasta, DJ
    Andrade-Gordon, P
    DeGaravilla, L
    Demarest, K
    Gunnet, J
    Look, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : A93 - A93
  • [33] Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist
    Coltamai, L.
    Bucher, M.
    Maillard, M. P.
    Shukla, U.
    Bohidar, N.
    Haskell, L.
    Bertelsen, K.
    Fedgchin, M.
    Vogt, B.
    Burnier, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) : 145 - 148
  • [34] Analysis of vasopressin V1a and V2 receptors distribution in the mammalian kidney
    Giesecke, T.
    Koshimizu, T.
    Kawahara, K.
    Bachmann, S.
    Mutig, K.
    ACTA PHYSIOLOGICA, 2016, 216
  • [35] Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor
    Mondritzki, T. Thomas
    Boehme, P.
    Sandner, P.
    Dinh, W.
    Hueser, J.
    Truebel, H.
    Kolkhof, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 335 - 335
  • [36] Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure
    Yatsu, T
    Tomura, Y
    Tahara, A
    Wada, K
    Kusayama, T
    Tsukada, J
    Tokioka, T
    Uchida, W
    Inagaki, O
    Iizumi, Y
    Tanaka, A
    Honda, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 376 (03) : 239 - 246
  • [37] 血管加压素V1a/V2受体拮抗剂Conivaptan
    张鸽
    药学进展, 2005, (03) : 144 - 145
  • [38] Pharmacological characterization of YMO87, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist
    Tahara, A
    Saito, M
    Sugimoto, T
    Tomura, Y
    Wada, K
    Kusayama, T
    Tsukada, J
    Ishii, N
    Yatsu, T
    Uchida, W
    Tanaka, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (01) : 63 - 69
  • [39] Satavaptan -: Vasopressin V2 antagonist treatment of hyponatremia treatment of cirrhotic ascites
    Revill, P.
    Serradell, N.
    Bolos, J.
    Bayes, M.
    DRUGS OF THE FUTURE, 2007, 32 (01) : 26 - 36
  • [40] In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
    Risvanis, J
    Naitoh, M
    Johnston, CI
    Burrell, LM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 381 (01) : 23 - 30
12345